GENNARO PAGANO, M.D., MSc., Ph.D.

GRENZACHERSTRASSE 124, 4070 BASEL, SWITZERLAND
+44 7949 8050 13 gennaro.pagano@roche.com

Physician-neuroscientist and pharma medical director with 10+ years of translational research in academia and early clinical development. Board-certified in movement disorders and geriatric neurology with broad hands-on experience across multiple therapeutic areas, including Parkinson's disease, Alzheimer's disease, common and rare movement disorders (e.g. Huntington's disease), epilepsy and sleep disorders. Doctor of Medicine (MD), Master in Epidemiology (MSc), Doctor of Philosophy (PhD) in Clinical Neuroscience and postdoctoral training in PET molecular imaging with focus on genetics, preclinical and prodromal Parkinson's disease.
Designed, implemented and led several Phase 0, 1 and Phase 2 proof-of-concept trials in academia and in industry, with 90+ peer-reviewed publications in the field of common and rare movement disorders and dementias (h-index: 31). Global regulatory experience with multiple interactions and face-to-face meetings (e.g. EMA, EunetHA, etc.). Servant leader encourages colleagues to step outside of their comfort zones and show intelligent disobedience, using a collaborative, inspiring and empowering style and micromanage-free guidance.

WORK EXPERIENCE

From	To	Position	Organization
2020	ongoing	Senior Principal Medical Director | Roche Pharma Research & Early Development, Basel, Switzerland *- completed PASADENA phase 2 study Part 1 within timelines and involved on the extended Prasinezumab Lifecycle team towards next steps in development* *- clinical and scientific leadership in the GSM(2) team (ph1-Go) and ENT1 inhibitors (ph 0-Go)* *- voting member for F. Hoffmann-La Roche Ltd in Parkinson's disease & Movement Disorders International Consortias (e.g. Michael J. Fox Foundation for Parkinson's disease consortia and Critical Path for Parkinson's disease)* *- explored long-term opportunities and threats in the area of movement disorders, in collaboration with Partnering and Global Product Strategy Competitive intelligence, evaluating options, and taking proactive steps to address them and to shape the competitive landscape*	F. Hoffmann-La Roche Ltd
2019	2020	Translational Medicine Leader | Roche Pharma Research & Early Development, Basel, Switzerland *- co-lead of movement disorders strategy workstream, interfaced with each department (e.g. Discovery, Biomarkers and Translational Technologies) and global function (e.g. Therapeutic Modalities, Pharmaceutical Sciences, Late Stage, Partnering)* *- clinical and scientific leadership in Prasinezumab (large molecule in Parkinson's disease) and GSM(2) (small molecule in Alzheimer's disease)* *- represented the Prasinezumab team at International Congresses (ADPD 2020, MDS 2019)* *- multiple regulatory interactions and face-to-face meetings (e.g. EMA, EunetHA, etc)* *- organized global ad boards for clinical development plans and biomarker strategies* *- main driver of clinical development plans in several Due Diligences and pre-Due Diligences*	F. Hoffmann-La Roche Ltd
2019	ongoing	Visiting Researcher | Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK *- supervised 2+ PhDs students and dissemination (e.g. publications) of the results of studies completed at King's College London*	Institute of Psychiatry, Psychology & Neuroscience, King's College London

2016	2019	Research & Development Leader for Neurodegeneration | UK National Parkinson Foundation Centre of Excellence for Parkinson's & Movement Disorders *- supervised 35+ clinical trials with focus on: (1) protocol development, in line with GCP regulations; (2) study set up; (3) study design; (4) regulatory and ethics submission, providing advice and assistance in the preparation of documentations for Ethics, HRA, ARSAC and for the submission and expedition of all necessary approvals for research protocols; (5) extensive experience in the recruitment of a high number of patients with a variety of neurodegenerative disorders and high retention rate into longitudinal and complex research studies* *- participated in defining the strategy of the Neurodegeneration Group* *- primary drafting, coauthoring, reviewing protocols and grants/funding applications* *- disseminated results to media and the press* *- 5+ direct reports and matrix coordination of 40+ individuals among MSc, PhDs, clinical research fellows, post-doc, clinicians and young PIs from diverse academic/scientific backgrounds*	UK National Parkinson Foundation Centre of Excellence for Parkinson's & Movement Disorders
2015	2019	NHS Consultant & Lily Safra Senior Fellow in Neurology | King's College London & King's College NHS Hospital *- 15+ clinical trials (e.g. opened the Parkinson's Progressive Markers Initiative – Genetics in UK) and neuroimaging projects using multimodal MRI imaging and PET tracers (e.g. [^{11}C]UCB-J, [^{11}C]PE2I etc.) in common (e.g. Parkinson's disease, progressive supranuclear palsy) and rare (e.g. multiple system atrophy, Huntington's disease, mutation carriers of LRRK2, A53T SNCA, GBA, PDE10A etc.) movement disorders* *- neurology lectures to medical students, consultants, and Parkinson's disease nurses* *- advanced movement disorder outpatients' clinics and led multidisciplinary team at the UK National Parkinson Foundation Centre of Excellence for Parkinson's disease & Movement disorders and at King's College NHS Hospital* *- 4+ direct reports (MSc and PhD students, each of those published a first name paper on top Neurology journals)*	King's College London & King's College NHS Hospital
2014	2015	NHS Consultant & Medical Research Council Clinical Research Fellow in Neurology | Imperial College London & Imperial NHS Trust *- 5+ phase 1 and phase 2 clinical trials and neuroimaging projects using PET imaging (e.g. [^{11}C]PHNO tracer in Parkinson's Disease patients with Dyskinesias and the Parkinson's Progressive Markers Initiative)* *- general neurology & movement disorders & deep brain stimulation outpatients' clinics* *- 3+ direct reports (MSc students, each of those published a first name paper on top Neurology journals)*	Imperial College London & Imperial NHS Trust & Hammersmith & Charing Cross hospitals
2013	2014	Fellowship in movement disorders | Cedars-Sinai Medical School, Los Angeles, US *- movement disorders & deep brain stimulation training and held movement disorders outpatients' clinic* *- 2+ research projects and filed a patent invention on "the role of noradrenergic system in Parkinson's disease"*	Cedars-Sinai Medical Center
2010	2014	Geriatric neurology | Federico II University, Naples, Italy *- memory & movement disorders outpatients' clinics* *- 10+ phase 1 and phase 2 clinical trials in Alzheimer's and Parkinson's disease testing potential disease-modifying treatments*	Federico II University

EDUCATION

From	To	Course
2018	2020	Executive Master in Business and Administration (EMBA) | Quantic School of Business and Technology, US
2015	2018	Doctor of Philosophy in Clinical Neuroscience (PhD) | Institute of Psychiatry, Psychology & Neuroscience, UK
2010	2015	Specialist Training in Geriatric Neurology | Federico II University, Italy
2011	2012	Master in Epidemiology, Cochrane Systematic review and Meta-Analysis (MSc) | University of Milan, Italy
2003	2009	Medical School 110/110 with first class honors (MD) | Federico II University, Italy

INDUSTRY & LEADERSHIP EXPERIENCE

1. Voting member for F. Hoffmann-La Roche Ltd in Parkinson's disease & Movement Disorders International Consortia (e.g. MJFF, CPP)
2. Clinical and scientific leadership of programs (e,g, Phase 2 Prasinezumab; Phase 0 GSM(2) and ENT1 inhibitors)
3. Co-leads of the movemend disorders strategy workstream
4. Main driver of clinical development plan in several Due Diligences and pre-Due Diligences
5. Research & Development Leader with 5+ direct reports and matrix coordination of 40+ individuals among MSc, PhDs, clinical research fellows, post-doc, clinicians and young PIs from diverse academic/scientific backgrounds (UK National Parkinson Foundation Centre of Excellence for Parkinson's & Movement Disorders)
6. Representative of all PhD Students (King's College London)
7. President of Rotaract Club Napoli (young branch of Rotary Club Napoli)
8. Representative of all Medicine Students (University of Naples Federico II) and all Students at High School

AWARDS & DISTINCTIONS *(selected from a total of 12)*

1. Ranked in the Top Italian Scientist in Neurosciences & Psychology (2020)
2. European Academy of Neurology Tournament – Runner-up Clinical Award for imaging in LRRK2 genetic movement disorders (2019)
3. Italian Professorship 'Abilitazione Scientifica Nazionale per Professore di seconda fascia' (2019)
4. Brain Travel Grant Award for SNMMI Congress 2017 (2017)
5. European Academy of Neurology Travel Grant Award (2017)
6. Movement Disorders Society Travel Grant Award (2017)
7. Best Poster for PhD Students, King's College London. Institute of Psychiatry, Psychology and Neuroscience (2017)
8. Lily Safra Hope Foundation PhD in Clinical Neurosciecne, Institute of Psychiatry, Psychology and Neuroscience (2015)

EDITORIAL EXPERIENCE *(selected from a total of 5)*

1. Editorial board of Frontiers in Neurology & Movement Disorders - Review Editor
2. Editorial board of Frontiers in Pharmacology - Review Editor
3. Editorial board of Frontiers in Physiology - Review Editor
4. Reviewer for: Movement Disorders, Brain, Neurology, European Journal of Neurology, Annals of Neurology, Neuroimage, Human Brain Mapping, Parkinsonism Relat Disord, etc.

INTERNATIONAL INVITED TALKS *(selected from a total of 102)*

1. 'Translational medicine journey in neurodegeneration: focus on alpha-synuclein' 2nd Brainstorming Research Assembly for Young Neuroscientists. BraYn 2019, Milan 14-16th November 2019
2. "Is Braak staging true for all Parkinson's disease patients?" 12th World Congress on Controversies in Neurology (CONy) Warsaw, Poland. 22-25th March 2018
3. "Is amyloid deposition a non-specific manifestation of aging?" 12th World Congress on Controversies in Neurology (CONy) Warsaw, Poland. 22-25th March 2018
4. "A vision of tomorrow: how can technology improve diagnosis and treatment for Parkinson's patients?" Edmond J. Safra Memorial Lecture. King's College London. 6th March 2018
5. "Changes in brain phosphodiesterase 10A expression in neurodegenerative basal ganglia disorders" Neuroimaging Seminars. Division of Neuroscience and Experimental Psychology, University of Manchester. 19th October 2017

SCIENTIFIC SOCIETIES MEMBERSHIPS *(selected from a total of 11)*

1. Movement Disorder Society
2. European Academy of Neurology
3. International Non-Motor Parkinson's Disease Study Group
4. Society of Nuclear Medicine and Molecular Imaging

TEACHING & STUDENT SUPERVISIONS *(selected from a total of 7)*

1. Lectures on movement disorders at UK National Parkinson Foundation Centre of Excellence for Parkinson's & Movement Disorders
2. Lectures on neurology and neuroscience to medical students, consultants, and Parkinson's disease nurses at King's College Hospital
3. Lectures on general neurology and psychiatry at MSc Clinical Neuroscience at Institute of Psychiatry, Psychology & Neuroscience
4. MSc and BSc Neuroscience Thesis Supervisor in Clinical Neuroscience and Neuroimaging at King's College London

PUBLICATIONS *(selected from a total of 97) - h-index: 31* (Google *Scholar) - *co-first authorship*

1. Pagano G, et al. In vivo evidence of Braak theory in individuals carriers of A53T alpha-synuclein mutations and with Lewy body diseases. ***Science Translational Medicine*** *2020 in submission*
2. Wilson H, Pagano G*, Mitochondrial complex 1, sigma 1 and synaptic vesicle 2A in early drug-naïve Parkinson's disease. ***Movement Disorders*** *2020 29 April;10.1002/mds.28064*
3. Wilson H, Dervenoulas G, Pagano G*, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. ***Lancet Neurology*** *2019 Aug;18(8):748-759.*
4. Pagano G, Niccolini F, Wilson H, et al. Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. ***Movement Disorders*** *2019 Oct;34(10):1505-1515.*
5. Wilson H, Dervenoulas G, Pagano G, et al. Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo 11C-BU99008 PET study. ***Brain****. 2019 Oct 1;142(10):3116-3128.*
6. Schulz J, Pagano G*, Bonfante J, et al. Nucleus basalis of Meynert degeneration precedes and predicts cognitive impairment in Parkinson's disease. ***Brain*** *2018 May 1;141(5):1501-1516.*
7. Wilson H, Pagano G, Yousaf T, et al. Predict cognitive decline with clinical markers in Parkinson's disease (PRECODE-1). ***J Neural Transm (Vienna)*** *2020 Jan;127(1):51-59.*
8. Yousaf T, Pagano G, Niccolini F, et al. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). ***J Neurol*** *2019 May;266(5):1203-1210.*
9. Pagano G. Politis M, Molecular Imaging of the Serotonergic System in Parkinson's Disease. ***Int Rev Neurobiol.*** *2018;141:173-210.*
10. Pagano G, De Micco R, Yousaf T, et al. REM behaviour disorder predicts motor progression and cognitive decline in Parkinson's disease. ***Neurology*** *2018 Aug 8. pii: 10.1212/WNL.0000000000006134.*
11. Pagano G, Polychronis S, et al. Diabetes Mellitus and Parkinson's disease. ***Neurology*** *2018 May 8;90(19):e1654-e1662.*
12. Pagano G, Yousaf T, Wilson H, et al. Constipation is not associated with DAT dopaminergic pathology in early de novo patients with Parkinson's disease. ***European Journal of Neurology*** *2017 Oct 27. doi: 10.1111/ene.13503.*
13. Pagano G, Niccolini F, Yousaf T, et al. Urinary dysfunction in early de novo patients with Parkinson's disease. ***Movement Disorders*** *2017 Jun;32(6):939-940.*
14. Pagano G, Yousaf T, Politis M. PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease. ***Curr Neurol Neurosci Rep.*** *2017 Oct 3;17(11):90. doi: 10.1007/s11910-017-0794-2.*
15. Pagano G, Niccolini F, Politis M. The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies. ***J Neural Transm (Vienna).*** *2017 Dec 20. doi: 10.1007/s00702-017-1823-7.*
16. Pagano G, Niccolini F, Fusar-Poli P, et al. Serotonin transporter in Parkinson's disease: A meta-analysis of positron emission tomography studies. ***Annals of Neurology*** *2017 Feb;81(2):171-180. doi: 10.1002/ana.24859.*
17. Chandra A, Valkimadi PE, Pagano G, et al; Alzheimer's Disease Neuroimaging Initiative. Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment. ***Hum Brain Mapp.*** 2019 Dec 15;40(18):5424-5442. doi: 10.1002/hbm.24782.
18. Niccolini F, Wilson H, Giordano B, Diamantopoulos K, Pagano G, et al. Sleep disturbances and gastrointestinal dysfunction are associated with thalamic atrophy in Parkinson's disease. ***BMC Neurosci.*** *2019 Oct 22;20(1):55.*
19. Polychronis S, Dervenoulas G, Yousaf T, Niccolini F, Pagano G, et al. Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson's patients. ***PLoS One*** *2019 Jul 25;14(7):e0214352.*
20. Polychronis S, Niccolini F, Pagano G, et al. Speech difficulties in early de novo patients with Parkinson's disease. ***Parkinsonism Relat Disord*** *2019 Jul;64:256-261.*
21. Maghzi H, Hogg EJ, Tan E, Pagano G, et al. Adrenoceptor agonists and antagonists and risk of Parkinson's disease. ***Movement Disorders*** *2019 Mar;34(3):442.*
22. Tondo G, Esposito M, Dervenoulas G, Wilson H, Politis M, Pagano G. Hybrid PET-MRI Applications in Movement Disorders. ***Int Rev Neurobiol.*** *2019;144:211-257.*
    Niccolini F, Mengacci NE, Yousaf T, Rabiner EA, Salpietro V, Pagano G, et al. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. ***Movement Disorders*** *2018 Dec;33(12):1961-1965..*
23. Niccolini F, Wilson H, Hirschbichler S, Yousaf T, Pagano G, et al. Disease-related patterns of *in vivo* pathology in Corticobasal syndrome. ***European Journal of Nuclear Medicine and Molecular Imaging*** *2018 Dec;45(13):2413-2425.*
24. Yousaf T, Pagano G, Niccolini F, et al. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. ***Journal of the Neurological Sciences*** *2018 Apr 15;387:220-227.*

25. Yousaf T, Pagano G, Niccolini F, et al. Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. ***Sleep Medicine*** *2018 Mar;43:25-30.*
26. Niccolini F, Wilson H, Pagano G. et al. Loss of phosphodiesterase 4 in Parkinson disease: Relevance to cognitive deficits. ***Neurology*** *2017 Aug 8;89(6):586-593.*
27. Niccolini F, Pagano G, Fusar-Poli P, et al. Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. ***J Neurol Neurosurg Psychiatry*** *2017 Sep 9. pii: jnnp-2017-316633*
28. Moonga I, Niccolini F, Wilson H, Pagano G, et al; Alzheimer's Disease Neuroimaging Initiative. Hypertension is associated with worse cognitive function and hippocampal hypometabolism in Alzheimer's disease. ***European Journal of Neurology*** *2017 Sep;24(9):1173-1182.*
29. Politis M, Pagano G, Niccolini F. Imaging in Parkinson's Disease. ***Int Rev Neurobiol.*** *2017;132:233-274.*
30. Pagano G, Molloy S, Bain PG, et al. Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson's disease. ***Neurology*** *2016 Dec 6;87(23):2451-2456.*
31. Pagano G, Niccolini F, Politis M. Imaging in Parkinson's disease. ***Clin Med (Lond).*** *2016 Aug;16(4):371-5.*
32. Pagano G, Niccolini N, Politis M Current status of PET imaging in Huntington's disease. ***European Journal of Nuclear Medicine and Molecular Imaging*** *2016 Jun;43(6):1171-82.*
33. Ashraghi MR, Pagano G*, Polychronis S, et al. Parkinson's Disease, Diabetes and Cognitive Impairment. ***Recent Pat Endocr Metab Immune Drug Discov*** *2016;10(1):11-21.*
34. Roy R, Niccolini F, Pagano G, et al. Cholinergic Imaging in Dementia spectrum disorders. ***European Journal of Nuclear Medicine and Molecular Imaging*** *2016 Jul;43(7):1376-86.*
35. Taylor S, Gafton J, Shah B, Pagano G, et al. Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism. ***Movement Disorders*** *2016 Mar;31(3):344-51.*
36. Pagano G, Ferrara N, et al. Age at onset and Parkinson's disease phenotype. ***Neurology*** *2015 Apr 12;86(15):1400-7.*
37. Pagano G, Rengo G, Pasqualetti G, et al. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis. ***J Neurol Neurosurg Psychiatry*** *2015 Jul;86(7):767-73.*
38. Pagano G, Tan EE, Haider JM, et al. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. ***Parkinsonism Relat Disord*** *2015 Feb;21(2):120-5.*
39. Santulli G, Pagano G, Sardu C, et al. Calcium release channel RyR2 regulates insulin release and glucose homeostasis. ***J Clin Invest*** *2015 May 1;125(5):1968-78*
40. Qamhawi Z, Towey D, Shah B, Pagano G, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. ***Brain*** *2015 Oct;138(Pt 10):2964-73.*